anti il 9 antibody (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
92
Structured Review
R&D Systems
anti il 9 antibody
Anti Il 9 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+il+9+antibody/Human+IL-9+Antibody/pm40445384-76-13-18
Average 92 stars, based on 5 article reviews
Anti Il 9 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+il+9+antibody/Human+IL-9+Antibody/pm40445384-76-13-18
Average 92 stars, based on 5 article reviews
anti il 9 antibody - by Bioz Stars,
2026-09
92/100 stars
Images
Related Articles
Cell Culture:Article Title: Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer. Article Snippet: Chemotherapy and immunotherapy yield survival benefits for muscle-invasive bladder cancer (MIBC) patients, in which tumor microenvironment has been found to exert crucial roles through tipping the balance between anti-tumor immunity and immune evasion.. This study aims to explore the clinical significance and therapeutic role of intratumoral interleukin-9-producing cells (IL-9+ cells) in MIBC.. 259 MIBC patients from two independent clinic centers were utilized for retrospective analysis in the study. Single Cell:Article Title: Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer. Article Snippet: Chemotherapy and immunotherapy yield survival benefits for muscle-invasive bladder cancer (MIBC) patients, in which tumor microenvironment has been found to exert crucial roles through tipping the balance between anti-tumor immunity and immune evasion.. This study aims to explore the clinical significance and therapeutic role of intratumoral interleukin-9-producing cells (IL-9+ cells) in MIBC.. 259 MIBC patients from two independent clinic centers were utilized for retrospective analysis in the study. Suspension:Article Title: Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer. Article Snippet: Chemotherapy and immunotherapy yield survival benefits for muscle-invasive bladder cancer (MIBC) patients, in which tumor microenvironment has been found to exert crucial roles through tipping the balance between anti-tumor immunity and immune evasion.. This study aims to explore the clinical significance and therapeutic role of intratumoral interleukin-9-producing cells (IL-9+ cells) in MIBC.. 259 MIBC patients from two independent clinic centers were utilized for retrospective analysis in the study. Incubation:Article Title: Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer. Article Snippet: Chemotherapy and immunotherapy yield survival benefits for muscle-invasive bladder cancer (MIBC) patients, in which tumor microenvironment has been found to exert crucial roles through tipping the balance between anti-tumor immunity and immune evasion.. This study aims to explore the clinical significance and therapeutic role of intratumoral interleukin-9-producing cells (IL-9+ cells) in MIBC.. 259 MIBC patients from two independent clinic centers were utilized for retrospective analysis in the study. Recombinant:Article Title: Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer. Article Snippet: Chemotherapy and immunotherapy yield survival benefits for muscle-invasive bladder cancer (MIBC) patients, in which tumor microenvironment has been found to exert crucial roles through tipping the balance between anti-tumor immunity and immune evasion.. This study aims to explore the clinical significance and therapeutic role of intratumoral interleukin-9-producing cells (IL-9+ cells) in MIBC.. 259 MIBC patients from two independent clinic centers were utilized for retrospective analysis in the study. Article Title: Group 2 innate lymphoid cells protect lung endothelial cells from pyroptosis in sepsis Article Snippet: .. Mice were treated i.t. with 1 μg recombinant murine IL-33 (BioLegend, San Diego, CA) or IL-25 and TSLP (R&D Systems, Minneapolis, MN) in a volume of 50 μl PBS/mouse for 24 h. Article Title: Intratumoral interleukin-9 delineates a distinct immunogenic class of gastric cancer patients with better prognosis and adjuvant chemotherapeutic response Article Snippet: In CD8 + T cells-deprived system, CD8 + T cells were depleted from single cell suspensions by negative selection using CD8 MicroBeads (Life Technologies). .. Recombinant human IL-9 (0.3 ng/ml, R&D Systems), Article Title: Intratumoral interleukin-9 delineates a distinct immunogenic class of gastric cancer patients with better prognosis and adjuvant chemotherapeutic response Article Snippet: In CD8+ T cells-deprived system, CD8+ T cells were depleted from single cell suspensions by negative selection using CD8 MicroBeads (Life Technologies). .. Recombinant human IL-9 (0.3 ng/ml, R&D Systems), Control:Article Title: Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer. Article Snippet: Chemotherapy and immunotherapy yield survival benefits for muscle-invasive bladder cancer (MIBC) patients, in which tumor microenvironment has been found to exert crucial roles through tipping the balance between anti-tumor immunity and immune evasion.. This study aims to explore the clinical significance and therapeutic role of intratumoral interleukin-9-producing cells (IL-9+ cells) in MIBC.. 259 MIBC patients from two independent clinic centers were utilized for retrospective analysis in the study. Article Title: Group 2 innate lymphoid cells protect lung endothelial cells from pyroptosis in sepsis Article Snippet: .. Mice were treated i.t. with 1 μg recombinant murine IL-33 (BioLegend, San Diego, CA) or IL-25 and TSLP (R&D Systems, Minneapolis, MN) in a volume of 50 μl PBS/mouse for 24 h. Article Title: Nitric oxide enhances Th9 cell differentiation and airway inflammation Article Snippet: .. In some experiments a neutralizing Mouse Assay:Article Title: Group 2 innate lymphoid cells protect lung endothelial cells from pyroptosis in sepsis Article Snippet: .. Mice were treated i.t. with 1 μg recombinant murine IL-33 (BioLegend, San Diego, CA) or IL-25 and TSLP (R&D Systems, Minneapolis, MN) in a volume of 50 μl PBS/mouse for 24 h. Injection:Article Title: Group 2 innate lymphoid cells protect lung endothelial cells from pyroptosis in sepsis Article Snippet: .. Mice were treated i.t. with 1 μg recombinant murine IL-33 (BioLegend, San Diego, CA) or IL-25 and TSLP (R&D Systems, Minneapolis, MN) in a volume of 50 μl PBS/mouse for 24 h. |